Platelet P2 receptors: From curiosity to clinical targets

Journal of the Autonomic Nervous System

Volumn 81, Issue 1-3, 2000, Pages 37-43

  Cusack, Noel J ^a   Hourani, Susanna M O ^b  

^a ADERIS Pharmaceuticals Inc   (United States)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

ADP; Antithrombotics; ATP; Hemostasis; Nucleotide analogs; Nucleotides; P2 receptors; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE ANTAGONIST; ARL 67085; CANGRELOR; RECEPTOR SUBTYPE; THROMBOCYTE P2 RECEPTOR; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

CALCIUM CELL LEVEL; CLINICAL TRIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 0034601234     PISSN: 01651838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1838(00)00151-X     Document Type: Article

References (75)

1. Born G.V.R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 194:1962;27-29.
2. Born G.V.R., Foulks J.G. Inhibition by a stable analog of adenosine triphosphate of platelet aggregation by adenosine diphosphate. Br. J. Pharmacol. 61:1977;87-89.
3. Boyer L., Romero-Avila T., Schachter J.B., Harden T.K. Identification of competitive antagonists of the P2Y(1) receptor. Mol. Pharmacol. 50:1996;1323-1329.
4. Burnstock G., Kennedy C. Is there a basis for distinguishing two types of P2 purinoceptor? Gen. Pharmacol. 16:1985;433-440.
5. 1 receptor, an adenosine-triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes. Blood. 91:1998;3172-3181.
6. Cooper D.M.F., Rodbell M. ADP is a potent inhibitor of human platelet plasma membrane adenylate cyclase. Nature. 282:1979;517-518.
7. Cristalli G., Mills D.C.B. Identification of a receptor for ADP on blood platelets by photoaffinity labelling. Biochem. J. 291:1993;875-881.
8. Cusack N.J., Hourani S.M.O. Partial agonist behaviour of adenosine 5′-O-(2-thiodiphosphate) on human platelets. Br. J. Pharmacol. 73:1981;405-408.
9. Cusack N.J., Hourani S.M.O. Effects of Rp and Sp diasteroisomers of adenosine 5′-O-(1-thiodiphosphate) on human platelets. Br. J. Pharmacol. 73:1981;409-412.
10. 1 of human platelet aggregation induced by adenosine 5′-O-(1-thiodiphosphate) and adenosine 5′-O-(2-thiodiphosphate). Br. J. Pharmacol. 75:1982;257-259.
11. Cusack N.J., Hourani S.M.O. Specific but noncompetitive inhibition by 2-alkylthio analogues of adenosine 5′-monophosphate and adenosine 5′-triphosphate of human platelet aggregation induced by adenosine 5′-diphosphate. Br. J. Pharmacol. 75:1982;397-400.
12. Cusack N.J., Hourani S.M.O. Adenosine 5′-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br. J. Pharmacol. 76:1982;221-227.
13. Cusack N.J., Hourani S.M.O. Inhibition by adenosine 5′-triphosphate of the actions on human platelets of 2-chloroadenosine 5′-diphosphate, 2-azidoadenosine 5′-diphosphate and 2-methylthioadenosine 5′-diphosphate. Br. J. Pharmacol. 77:1982;329-333.
14. 2T-purinoceptors mediating human platelet aggregation by ADP. Drug Dev. Res. 37:1996;212-222.
15. Daniel J.L., Dangelmaier C.A., Jin J., Ashby B., Smith J.B., Kunapuli S.P. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem. 273:1998;2024-2029.
16. Enjyoji K., Sevigny J., Lin Y., Frenette P.S., Christie P.D., Esch J.S. II, Imai M., Edelberg J.M., Rayburn H., Lech M., Beeler D.L., Csizmadia E., Wagner D.D., Robson S.C., Rosenberg R.D. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat. Med. 5:1999;1010-1017.
17. 1-deficient mice. Nat. Med. 5:1999;1199-1202.
18. ADP-receptors. Br. J. Pharmacol. 124:1998;157-164.
19. Gaarder A., Jonsen L., Laland S., Hellem A., Owren P.A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature. 192:1961;531-532.
20. Gachet C., Cazenave J.-P., Ohlmann P., Hilf G., Wieland T., Jakobs K.H. ADP receptor-induced activation of guanine nucleotide-binding proteins in human platelet membranes. Eur. J. Biochem. 207:1992;259-263.
21. Gachet C., Cattaneo M., Ohlmann P., Lecchi A., Chevalier J., Cassel D., Mannucci P.M., Cazenave J.-P. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br. J. Haematol. 91:1995;434-444.
22. Gachet C., Hechler B., Léon C., Vial C., Leray C., Ohlmann P., Cazenave J.-P. Activation of ADP receptors and platelet function. Thromb. Haemost. 78:1997;271-275.
23. Gordon J.L. Extracellular ATP: effects, sources and fate. Biochem. J. 233:1986;309-319.
24. Gough G., Maguire M.H., Penglis F. Analogues of adenosine 5′-diphosphate - new platelet aggregators. Influence of purine ring and phosphate chain substitutions on the platelet aggregatory potency of adenosine 5′-diphosphate. Mol. Pharmacol. 8:1972;170-177.
25. 2T-purinoceptors on human blood platelets. Br. J. Pharmacol. 108:1993;728-733.
26. Hall D.A., Hourani S.M.O. Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine 5′-diphosphate in human platelets. Biochem. Pharmacol. 47:1994;1013-1018.
27. Hall D.A., Frost V., Hourani S.M.O. Effects of extracellular divalent cations on responses of human blood platelets to adenosine 5′-diphosphate. Biochem. Pharmacol. 48:1994;1319-1326.
28. Hallam T.J., Rink T.J. Responses to adenosine diphosphate in human platelets loaded with the fluorescent calcium indicator quin2. J. Physiol. 368:1985;131-146.
29. Harden T.K., Nicholas R.A., Schachter J.B., Lazarowski E.R., Boyer J.L. Pharmacological selectivities of molecularly defined subtypes of P2Y receptors. Turner J.T., Weisman G.A., Fedan J.S. The P2 Nucleotide Receptors. 1998;109-134 Humana Press, Totowa, NJ.
30. Haslam R.J., Cusack N.J. Blood platelet receptors for ADP and for adenosine. Burnstock G. Purinergic Receptor: Receptors and Recognition Series B. Vol. 12:1981;222-285 Chapman and Hall, London.
31. Hechler B., Léon C., Vial C., Vigne P., Frelin C., Cazenave J.-P., Gachet C. The P2Y(1) receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood. 92:1998;152-159.
32. 1 receptor: similarities to the platelet ADP receptor. Mol. Pharmacol. 53:1998;727-733.
33. Hourani S.M.O., Cusack N.J. Pharmacological receptors on blood platelets. Pharmacol. Rev. 43:1991;243-298.
34. Hourani S.M.O., Hall D.A. ADP receptors on human blood platelets. Trends Pharmacol. Sci. 15:1994;103-108.
35. Hourani S.M.O., Hall D.A. P2T purinoceptors: ADP receptors on platelets. Ciba Found. Symp. 198:1996;52-69.
36. Hourani S.M.O., Welford L.A., Cusack N.J. Effects of 2-methylthioadenosine 5′-methylenetriphosphonate and 2-ethylthioadenosine 5′-monophosphate on human platelet aggregation induced by adenosine 5′-diphosphate. Drug Dev. Res. 38:1996;12-28.
37. 2T purinoceptors. Br. J. Pharmacol. 113:1994;1057-1063.
38. 2T-purinoceptor antagonist, FPL 67085 in vitro and in the anesthetized rat in vivo. Br. J. Pharmacol. 115:1995;1110-1116.
39. 2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol. Sci. 16:1995;179-181.
40. Ingall A.H., Dixon J., Bailey A., Coombs M.E., Cox D., McInally J.I., Hunt S.F., Kindon N.D., Teobald B.J., Willis P.A., Humphries R.G., Leff P., Clegg J.A., Smith J.A., Tomlinson W. Antagonists of the P2Y receptor: a novel approach to antithrombotic therapy. J. Med. Chem. 42:1999;213-220.
41. 2T receptors. Br. J. Pharmacol. 129:2000;275-282.
42. Jin J., Kunapuli S.P. Coactivation of two different G protein-coupled receptors in essential for ADP-induced platelet aggregation. Proc. Natl. Acad. Sci. USA. 95:1998;8070-8074.
43. Jin J., Daniel J.L., Kunapuli S.P. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 273:1998;2030-2034.
44. Kunapuli S.P. Multiple P2 receptor subtypes on platelets; a new interpretation of their function. Trends Pharmacol. Sci. 19:1998;391-394.
45. 1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett. 403:1997;26-30.
46. Léon C., Hechler B., Freund M., Eckly A., Vial C., Ohlmann P., Dierich A., LeMeur M., Cazenave J.-P., Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J. Clin. Invest. 104:1999;1731-1737.
47. Macfarlane D.E., Mills D.C.B. The effects of ATP on platelets: evidence against the central role of released ADP in primary aggregation. Blood. 46:1975;309-320.
48. 32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J. Clin. Invest. 71:1983;420-425.
49. 2T purinoceptors in human platelets. J. Biol. Chem. 271:1996;2879-2881.
50. McClure M.O., Kakker A., Cusack N.J., Born G.V.R. Evidence for the dependence of arterial haemostasis on ADP. Proc. R. Soc. London Biol. 234:1988;255-262.
51. Mills D.C.B. ADP receptors on platelets. Blood. 76:1996;835-856.
52. Mills D.C.B., Smith J.B. The control of platelet responsiveness by agents that influence cyclic AMP metabolism. Ann. NY Acad. Sci. 201:1972;391-399.
53. Mills D.C.B., Puri R., Hu C.-J., Minniti C., Grana G., Freedman M.D., Colman R.F., Colman R.W. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler. Thromb. 12:1992;430-436.
54. Nassim M.A., Gardner J.J., Wilkinson D., Corfield J.E., Rudol L., Wyld P.J. The short acting P(2T)-purinoceptor antagonist, FPL 67085, reliably, reversibly and safely inhibits ADP-induced platelet aggregation ex vivo in man. Br. J. Pharmacol. 39:1995;198.
55. Offermanns S., Toombs C.F., Hu Y.-H., Simon M.I. Defective platelet activation in Gq-deficient mice. Nature. 389:1997;183-186.
56. 2 proteins. Biochem. J. 312:1995;775-779.
57. Oury C., Toth-Zsamboki, van Geet C., Nilius B., Vermylen J., Hoylaerts M.F. A dominant mutation in the platelet P2X1 ADP receptor causes severe bleeding disorder. Important role of P2X1 in ADP-induced platelet aggregation. Blood. 94:(Suppl. 1):1999;618a. Abstr. 2747.
58. Park H.-S., Hourani S.M.O. Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adenosine 5′-diphosphate (ADP) in human platelets. Br. J. Pharmacol. 127:1999;1359-1366.
59. Park H.-S., Tennant J.P., Waktolla G.F., Sarkardei S., Kass G.E.N., Hourani S.M.O. Effects of adenosine 3′-phosphate 5′-phosphosulfate on P2 receptors in platelets and smooth muscle preparations. Drug Dev. Res. 45:1998;67-73.
60. Sage S.O., Rink T.J. The kinetics of changes in intracellular calcium concentration in fura-2-loaded human platelets. J. Biol. Chem. 262:1987;16364-16369.
61. Sage S.O., Merritt J.E., Hallam T.J., Rink T.J. Receptor-mediated calcium entry in fura-2-loaded human platelets stimulated with ADP and thrombin. Biochem. J. 258:1989;923-926.
62. 2+ store. Biochem. J. 265:1990;675-680.
63. Sage S.O., Mahaut-Smith M.P., Rink T.J. Calcium entry in nonexcitable cell: lessons from human platelets. News Physiol. Sci. 7:1992;108-113.
64. Sage S.O., MacKenzie A.B., Jenner S., Mahaut-Smith M.P. Purinoceptor-evoked calcium signaling in human platelets. Prostaglandins Leukot. Essent. Fatty Acids. 57:1997;435-438.
65. Sanderson H.M., Heptinstall S., Vickers J., Losche W. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood. Blood Coag. Fibrinol. 7:1996;245-248.
66. 1 in ADP-induced platelet activation. FEBS Lett. 422:1998;291-295.
67. Savi P., Nurden P., Nurden A.T., Levy-Toledano S., Herbert J.-M. Clopidogrel: a review of its mechanism of action. Platelets. 9:1998;251-255.
68. 2X1 purinoceptor expressed on human platelets. Biochem. Biophys. Res. Commun. 242:1998;525-528.
69. 2Y1-purinoceptor. Br. J. Pharmacol. 118:1996;167-173.
70. 1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression. J. Biol. Chem. 273:1998;11544-11547.
71. 2X receptor for extracellular ATP. Nature. 371:1994;516-519.
72. 1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb. Haemost. 78:1997;1500-1504.
73. Webb T.E., Simon J., Krishek B.J., Bateson A.N., Smart T.G., King B.F., Burnstock G., Barnard E.A. Cloning and functional expression of a brain G-protein coupled ATP receptor. FEBS Lett. 324:1993;219-225.
74. 2Y purinoceptor in rat brain microvascular endothelial cells couples to inhibition of adenylate cyclase. Br. J. Pharmacol. 119:1996;1385-1392.
75. Zawilska K.M., Born G.V.R., Begent N.A. Effect of ADP-utilizing enzymes on the arterial bleeding time in rats and rabbits. Br. J. Haematol. 50:1982;317-325.